<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01169116</url>
  </required_header>
  <id_info>
    <org_study_id>3592010</org_study_id>
    <nct_id>NCT01169116</nct_id>
  </id_info>
  <brief_title>Exclusive Hypofractionated Stereotactic Radiotherapy in Non-resectable Single Brain Metastasis</brief_title>
  <official_title>Exclusive Hypofractionated Stereotactic Radiotherapy in Non-resectable Single Brain Metastasis: Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barretos Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Barretos Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with single brain metastasis without other metastatic site have a better prognosis,&#xD;
      and they need a better brain metastasis control. For non-resectable and non-radiosurgical&#xD;
      brain metastasis, the gold standard treatment is whole-brain irradiation with 30 Gy in 10&#xD;
      fractions, but the local control is not achieved in most of the cases. This study investigate&#xD;
      the possibility to increase radiation dose in this metastasis with exclusive hypofractionated&#xD;
      stereotactic radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the planning, patients will undergo magnetic resonance imaging (MRI) 1.5 to 3 Tesla, with&#xD;
      contrast and volumetric reconstruction of 1 mm and can be used MRI from the diagnosis of&#xD;
      metastasis, if it is compatible with the planning system. Then, there will be individualized&#xD;
      mask Mask Set for One Patient 41100 (BrainLAB AG, Heimstetten, Germany) for each patient.&#xD;
      Patients will undergo computed tomography (CT) without contrast with 1-mm slices with&#xD;
      tracking and stereotactic fixation. The images of MRI and CT are fused in the planning system&#xD;
      IPLAN version 4.1 (BrainLAB AG, Heimstetten, Germany), where the plan will be implemented.&#xD;
      The clinical target volume (CTV) is the macroscopic disease (GTV) displayed on the sign of T1&#xD;
      contrast. The planning target volume (PTV) is the CTV with 3-mm margin in all directions. Can&#xD;
      be used multiple dynamic arcs, static conformal multiple fields, multiple static fields&#xD;
      modulated and multiple static arcs. The dose-fractionation scheme will be 4 fractions of 7 Gy&#xD;
      at the periphery of the PTV, a once daily on 4 consecutive working days. The dose to the PTV&#xD;
      encompassing areas of the brainstem or optic tract will be reduced by 20%. The plans will be&#xD;
      standardized at the isocenter. The isodose prescription will be the largest isodose that&#xD;
      meets the following criteria: isodose covering at least 95% of the PTV with the prescription&#xD;
      dose (V100 ≥ 95%) and 95% of prescription dose covering at least 99% of the PTV (V95 ≥ 99%).&#xD;
      The maximum dose should be less than 35 Gy. The dose constraint reported by Ernst-Stecken et&#xD;
      al will be respected at the expense of prescription isodose, where the normal brain volume&#xD;
      (total brain volume less volume PTV) of 20 cc will not receive a dose of 4 Gy per fraction or&#xD;
      larger, there is no maximum size limit of metastasis to be included in the study. Use as an&#xD;
      index of compliance reported by the Paddick et al and Radiation Therapy Oncology Group&#xD;
      (RTOG). Tests will be done for collision safety tests and quality control to ensure the&#xD;
      alignment of isocenters radiation, mechanical and coincidence of lasers (Winston-Lutz test).&#xD;
      After all, the patients are treated with 6-MeV photons in the linear accelerator Varian&#xD;
      Clinac 600 CD (Varian Medical Systems, Palo Alto, CA, USA) with a system of &quot;micromultileaf&quot;&#xD;
      m3 (BrainLAB AG, Heimstetten, Germany).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No participants enrolled.&#xD;
  </why_stopped>
  <start_date>July 2010</start_date>
  <primary_completion_date type="Anticipated">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>feasibility</measure>
    <time_frame>1 year</time_frame>
    <description>Through this study we prospectively evaluate the alternative of performing exclusive hypofractionated stereotactic radiotherapy for patients with single brain metastasis that is not eligible for surgery or radiosurgery, with a good prognosis for survival and lower risk of metachronous brain metastases, the primary objective being to verify whether the treatment is feasible in clinical practice.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>1 year</time_frame>
    <description>As a secondary objective, we will evaluate local control, tumor reduction, quality of life, overall survival, whole-brain irradiation free survival and acute and late toxicities related to treatment.</description>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Cancer</condition>
  <condition>Metastasis</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>hypofractionated stereotactic radiotherapy</intervention_name>
    <description>hypofractionated stereotactic radiotherapy with 4 fractions of 7 Gy at the periphery of the brain metastasis with 3 mm margin.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histopathology of primary tumors: all but the primary characteristics of melanoma&#xD;
             cancer, small cell lung cancer, germ cell tumors, leukemia or lymphoma, or primary&#xD;
             central nervous system.&#xD;
&#xD;
          -  Primary-site: controlled, meaning operated and / or irradiated tumor activity without&#xD;
             detectable local&#xD;
&#xD;
          -  Meningeal dissemination: none&#xD;
&#xD;
          -  Extra-cranial metastases: none&#xD;
&#xD;
          -  Pre-irradiation brain: absent&#xD;
&#xD;
          -  Number of brain metastases: one&#xD;
&#xD;
          -  Location of brain metastasis: brain regions not eligible for surgery (such as the&#xD;
             hippocampus, amygdala, motor area, eloquent cortex, thalamus, hypothalamus, basal&#xD;
             ganglia, optic tract, midbrain, pons, medulla, corpus callosum and internal capsule)&#xD;
             or radiosurgery( metastasis &lt;5 mm from the thalamus, hypothalamus, basal ganglia,&#xD;
             optic tract, midbrain, pons, medulla, corpus callosum and internal capsule, and / or ≥&#xD;
             10 ml or ≥ 3 cm in greatest diameter, or 10 ml tissue receiving ≥ 12 Gy).&#xD;
&#xD;
          -  Karnofsky Performance Status ≥ 70%&#xD;
&#xD;
          -  Informed consent: authorized&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients that don't have the eligibility below&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo A Nakamura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barretos Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barretos Cancer Hospital</name>
      <address>
        <city>Barretos</city>
        <state>São Paulo</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>July 22, 2010</study_first_submitted>
  <study_first_submitted_qc>July 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2010</study_first_posted>
  <last_update_submitted>February 2, 2014</last_update_submitted>
  <last_update_submitted_qc>February 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radiotherapy</keyword>
  <keyword>radiation oncology</keyword>
  <keyword>brain metastasis</keyword>
  <keyword>metastases</keyword>
  <keyword>radiosurgery</keyword>
  <keyword>neurosurgery</keyword>
  <keyword>hypofractionation</keyword>
  <keyword>stereotaxy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

